쥐 장에서 T4 박테리오파지와 대장균 상호작용: 생체 내 숙주-박테리오파지 역학 연구를 위한 프로토타입 모델

Executive Industry Relevance

Standardized in vivo models for bacteriophage-host interactions are critical for de-risking microbiome-targeted therapeutic strategies and understanding phage-driven modulation of gut bacterial populations. This protocol enables quantitative assessment of phage and bacterial dynamics in the murine intestine, supporting predictive confidence in translational microbiome research. Its adaptability to other phage-bacterial pairs positions it as a foundational tool for early discovery and mechanistic validation in biopharma pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of phage-bacteria-immune system interactions in a controlled in vivo setting.
• Supports functional validation of phage impact on bacterial colonization and persistence.
• Facilitates mechanistic de-risking for microbiome-targeted interventions.
• Provides quantitative outputs for hypothesis-driven target selection.

Screening & Assay Development

• Establishes reproducible protocols for phage lysate preparation and titration.
• Delivers standardized enumeration of both phage and bacterial populations in fecal samples.
• Enables assay scalability and cross-study comparability for microbiome research.
• Supports reliable evaluation of phage efficacy and host response in vivo.

Translational & Preclinical Research

• Aligns with disease-relevant models for studying phageome disruptions linked to gut disorders.
• Provides continuity from discovery to preclinical validation of microbiome-modulating agents.
• Enables risk-adjusted advancement decisions for phage-based therapeutic candidates.
• Supports biomarker development through quantitative measurement of phage and bacterial levels.

Pipeline & Workflow Integration

This protocol integrates into the discovery-to-preclinical continuum for microbiome-targeted R&D, enabling robust hypothesis testing and quantitative readouts for lead identification and validation.

• Discovery Biology: Quantifies phage and bacterial levels to clarify host-phage dynamics and biological mechanisms.
• Screening: Provides reproducible enumeration assays for phage and bacterial populations in murine models.
• Analytics: Delivers plaque and colony forming unit measurements for comparative analysis across experimental conditions.
• Translational Research: Supports modeling of disease-relevant phageome disruptions and therapeutic interventions.
• Enterprise Reuse: Protocol adaptability enables application across diverse phage-bacterial systems and research programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in microbiome-targeted discovery and reduces mechanistic ambiguity.
• Operational Value: Standardizes in vivo phage-bacteria quantification and enhances reproducibility.
• Strategic Value: Informs go/no-go decisions for phage-based assets and improves capital allocation.
• Portfolio Impact: Enables risk-adjusted prioritization of microbiome-modulating candidates.

Implementation Considerations

• Requires expertise in bacteriophage biology, murine models, and quantitative microbiology.
• Needs access to sterile culture facilities, centrifugation, filtration, and analytical instrumentation for enumeration.
• Demands rigorous cross-team standardization for reproducibility and data comparability.
• Adaptable to other phage-bacterial pairs with protocol modifications as supported by the source.
• Limitations include model-specific variables and the need for precise quantification of both phage and bacterial populations.

Biopharma FAQs